MWA
CMMB

Moser Wealth Advisors’s Chemomab Therapeutics CMMB Stock Holding History

Moser Wealth Advisors’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-125
Closed -$545 – 202
2025
Q1 		$545 Hold
125
– – ﹤0.01% 158
2024
Q4 		$905 Hold
125
– – ﹤0.01% 136
2024
Q3 		$785 Hold
125
– – ﹤0.01% 139
2024
Q2 		$456 Hold
125
– – ﹤0.01% 148
2024
Q1 		$390 Hold
125
– – ﹤0.01% 146
2023
Q4 		$255 Hold
125
– – ﹤0.01% 140
2023
Q3 		$448 Buy
+125
New +$584 ﹤0.01% 135

Other funds holding CMMB

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
YLHM
Yelin Lapidot Holdings Management Tel Aviv, Israel $480M AUM 42.17% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $8.11B AUM 24.74% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Moser Wealth Advisors's CMMB Position: Q2 2025 in Review

Moser Wealth Advisors sold out of Chemomab Therapeutics (CMMB) in Q2 2025, closing a stake of 125 shares — an estimated $545 sold.

Moser Wealth Advisors first reported a position in CMMB in Q3 2023 and held it in 7 quarters. The position peaked at $905 in Q4 2024. 14 funds tracked by Wall St. Rank hold CMMB as of Q2 2025.

  • Moser Wealth Advisors reported no remaining Chemomab Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Moser Wealth Advisors sold 125 Chemomab Therapeutics shares in Q2 2025, an estimated $545.
  • Moser Wealth Advisors first reported a position in Chemomab Therapeutics in Q3 2023 and held it in 7 quarters.
  • Moser Wealth Advisors's Chemomab Therapeutics position peaked at $905 in Q4 2024.
  • 14 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q2 2025.

Based on Moser Wealth Advisors's 13F filing for Q2 2025, filed 31 Jul 2025.